What’s the worst way to spend $1.2 million? Will genetic testing become as common as a physical? And where were you in 2001?
We dig into all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Stay tuned for a chat about the no good, very bad day Novartis had when the world got wind of its ties to President Trump’s personal attorney, a discussion of how the world’s biggest cancer conference used to be the Wild West for investors, and an exploration of one health system’s plan to bring genomics to the masses. Also STAT’s Eric Boodman joins us to talk about how a pricey new gene therapy has created a fascinating situation in Amish country.
For more on what we discuss, here’s the latest on Novartis; here’s Eric’s story on Spark Therapeutics; and here’s more on the plot to sequence rank-and-file patients.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].